Curated News
By: NewsRamp Editorial Staff
December 11, 2025

VolitionRx Unveils Breakthrough Capture-Seq™ for 100% Accurate Cancer Detection

Discuss on LinkedIn Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • VolitionRx's new Capture-Seq method offers a potential edge in cancer detection with 100% accuracy in early trials, creating opportunities for licensing and portfolio expansion.
  • VolitionRx's Capture-Seq method analyzes transcription factor-protected DNA fragments in blood by focusing on chromosomal context, achieving 180-fold enrichment to overcome background noise in liquid biopsies.
  • This technology could improve cancer detection and monitoring, potentially saving lives through earlier diagnosis and better treatment outcomes for patients worldwide.
  • VolitionRx discovered a way to detect cancer with perfect accuracy in initial tests by analyzing tiny DNA fragments that transcription factors protect in blood.

Impact - Why it Matters

This development represents a potential paradigm shift in oncology. Current cancer screening methods like colonoscopies or mammograms can be invasive, expensive, and have variable accuracy, especially for early-stage disease. Liquid biopsies that analyze circulating tumor DNA (ctDNA) have emerged as a promising non-invasive alternative, but they often struggle with low signal-to-noise ratios, making early detection difficult. Volition's Capture-Seq™ method directly addresses this core technical hurdle with its 180-fold enrichment, enabling the detection of ultrashort DNA fragments bound to transcription factors. The reported 100% sensitivity and specificity in an initial cohort, if validated in larger studies, could lead to a simple blood test capable of detecting multiple cancers at their earliest, most treatable stages. This would dramatically improve survival rates, reduce healthcare costs associated with late-stage treatment, and alleviate patient anxiety through less invasive monitoring. It positions Volition at the forefront of the multi-billion dollar liquid biopsy market, with implications for personalized medicine and population-wide cancer screening programs.

Summary

VolitionRx Ltd., a multi-national epigenetics company trading on the NYSE American under the symbol VNRX, has announced a significant breakthrough in cancer detection with the preprint release of research on its new Capture-Seq™ method. This innovative technology analyzes transcription factor–protected ultrashort DNA fragments in blood, presenting them as potential low-cost cancer biomarkers. The core achievement, detailed in the manuscript "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq," is a remarkable 180-fold enrichment of transcription factor–bound fragments. This was accomplished by focusing on DNA in its natural chromosomal context rather than chemically extracted DNA, effectively overcoming the persistent challenge of overwhelming background noise that has long plagued liquid biopsy testing. The company is actively developing two patent-pending technologies to isolate these ultrashort DNA fragments and is in discussions with potential licensing partners to explore commercial applications, which may include an expansion of its existing Nu.Q® portfolio.

Early validation of this new biomarker class is highly promising, with findings from a 70-person training cohort showing 100 percent sensitivity and 100 percent specificity across several cancers, including early-stage disease. This level of accuracy in initial studies underscores the transformative potential of Capture-Seq™ for non-invasive cancer screening. The research was disseminated via BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on the biotechnology and life sciences sectors. BioMedWire provides services like access to a vast network of wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, and enhanced press release distribution to ensure maximum impact for news in this field.

Volition is dedicated to advancing the science of epigenetics with the goal of saving lives and improving patient outcomes through earlier disease detection and monitoring. The company's research and development is centered in Belgium, with additional operations in the U.S. and London. Their broader mission involves developing simple, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and conditions associated with NETosis like sepsis. The potential for early detection offered by technologies like Capture-Seq™ could profoundly extend patient lifespans and enhance quality of life. For further details, the full press release is available to view, and more information about the company can be found on the Volition website.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Unveils Breakthrough Capture-Seq™ for 100% Accurate Cancer Detection

blockchain registration record for this content.